In 2008 Visintin et al. [29] described the Luminex® based panel of CA125, IGF-2, MIF, PRL, OPN and leptin as “the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer”. Here, MUC16 is linked to ovarian carcinoma.